Richard M. Barnes
Richard M. Barnes
Mr. Barnes is a founding partner of the firm and a graduate of the Georgetown University Law Center. He represents clients in complex tort, commercial, and product liability litigation. He has been recognized as a leading practitioner in these fields and most recently was awarded 2015’s Leadership in Law Award from The Daily Record. During his career, he has represented a variety of clients in disputes involving pharmaceuticals, medical devices, patents, trademarks and the Lanham Act, antitrust, breach of contract, unfair trade practices, aviation, commercial torts, covenants not to compete, and state procurement laws. He has defended companies in federal and state court class actions in Maryland, West Virginia, Alabama, Ohio, Pennsylvania, and California. His recent experience follows:
In June of 2017, Mr. Barnes and Ms. Woolf obtained a preliminary injunction on behalf of a medical device client preventing a consultant and former employer from competing. Also, in June 2017, he, Ms. Woolf, and Mr. Stikeleather successfully defeated plaintiffs’ motion for class certification in a decade-long class action pending in the Eastern District of Pennsylvania.
In 2015, Mr. Barnes and Ms. Woolf defeated a multi-million dollar claim for patent royalties based on various endodontic patents and inventions. His client, Dentsply International, was also relieved of its obligation to pay future royalties on several of the disputed patents and inventions. In December of 2013, Mr. Barnes and Ms. Woolf successfully defended Dentsply International in a three-week California UCL class action trial in San Francisco Superior Court. In 2013, he also successfully litigated a complex state procurement dispute before the Maryland Board of Contract Appeals on behalf of an institutional pharmacy. Mr. Barnes has also tried to verdict complicated multi-plaintiff product liability, pharmaceutical, and medical device cases. He has briefed or argued cases before the United States Supreme Court and various state and federal appellate courts. He is currently serving as national counsel in two pharmaceutical litigations involving over-the-counter medications.
Representative clients include Pfizer Inc, Wyeth, Telectronics Pacing Systems, Inc., Pacific Dunlop, Ltd., Dentsply Sirona, Danaher Corporation, Johnson & Johnson, DePuy Orthopedics, L. Perrigo Company, Nissan Motor Credit Corporation, Lafarge, ARINC, Vermont Talc, A.H. Robins Co., Gruss & Co., Correct Rx Pharmacy, and several local businesses.
Mr. Barnes’ significant representations include trials for Pfizer Inc and/or Wyeth relating to the Bjork Shiley Mechanical Heart Valve (1985-1999), Rezulin (2000-2004), the Howmedica Unicompartmental Knee (2001-2004), Diet Drugs (2003-2005), and Neurontin (2007-2011). He is currently representing Pfizer in several matters including litigation involving Advil and Reglan. Mr. Barnes has represented Pfizer in the hormone therapy litigation in cases in several jurisdictions including Maryland, Pennsylvania, Minnesota, West Virginia, and Virginia. He also had significant responsibilities for preparing and presenting scientific evidence in the Celebrex, Bextra, and Chantix Litigations. He has briefed and argued several Daubert motions in pharmaceutical cases. Mr. Barnes served as national counsel to Pfizer Inc and its subsidiaries for claims and disputes arising from the manufacture and sale of the Duracon Unicompartmental Knee and over-the-counter pain relievers. In addition, he obtained a temporary restraining order and permanent injunction against the owner of a pornographic web site in Maryland for the infringement and dilution of Pfizer's "Viagra" trademark.
Mr. Barnes served on the firm's national counsel team representing Telectronics Pacing Systems, Inc. in connection with hundreds of claims arising out of the alleged failure of pacemaker leads. See In Re Telectronics Pacing Systems, Accufix Atrial "J" Leads Litigation, MDL-1057. In this role, he was responsible for the presentation of scientific, engineering, and regulatory evidence.
Mr. Barnes represents L. Perrigo Company in cases in California, Maryland, Virginia, Pennsylvania, New Jersey, and the District of Columbia involving over-the-counter medications including aspirin (Reyes Syndrome), acetaminophen, and ibuprofen.
Mr. Barnes also represented ARINC, a provider of Advanced Information Management, for a rail control center in the matter of the Fort Totten Metrorail Accident Cases in the United States District Court for the District of Columbia. He was primarily responsible for preparing and presenting technical and scientific evidence pertaining to software design, train tracking algorithms, alarm management, and accident reconstruction.
Mr. Barnes is a member of the Maryland and the District of Columbia bars, and is admitted to practice before the United States District Court for the District of Maryland, the United States District Court for the District of Columbia, the United States Supreme Court, and the United States Court of Appeals for the Fourth, Sixth, Ninth, and Eleventh Circuits.
Professional and Civic Associations
Selected Cases and Decisions
United States Supreme Court case
Federal Appellate Court cases
Federal District Court cases
State Appellate Court cases
Honors and Awards
Class Action and Other Litigation Matters
Center City Periodontists, P.C. v. Dentsply International, Inc., --- F.R.D. ----, 2017 WL 3142119 (E.D. Pa. July 24, 2017) Mr. Barnes was part of the Goodell team that, in 2017, successfully defeated a motion for class certification filed against the same dental device manufacturer in a decade-long class action in Pennsylvania federal court. The 36-page memorandum opinion, which followed six days of hearings on the motion to certify, denied class certification on a multitude of bases. The district court judge found that the plaintiffs failed to meet three of the four requirements under Rule 23(a): typicality, adequacy, and numerosity and Rule 23(b)(3)’s requirements that common questions of law or fact predominate over individual questions and that a class action is superior to other available methods for adjudicating the dispute. The court further agreed with Goodell’s argument that the proposed class and subclasses were not objectively ascertainable and granted the Daubert motions to exclude the plaintiffs’ economic damages and FDA regulatory experts. In 2013, the team had obtained dismissal of claims for negligence and alleged violations of the New Jersey Consumer Fraud Act. That opinion, 2013 WL 3956284, is believed to be the first to hold that the NJCFA does not apply to the sale of prescription medical devices, which are not “merchandise” available to the public under the Act.